Oncology Practice Management Issues

May 2017, Vol 7, No 5

Physician Burnout in the Oncology Practice Setting

Meg Barbor, MPH

Oncology Practice Conference 2017

Orlando, FL—Burnout is a syndrome that includes feeling exhausted, cynical, and ineffective at work. Recognizing the triad of symptoms in the oncology setting is the first step to identifying physician burnout, said Anthony L. Back, MD, Professor, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, at ASCO’s first Oncology Practice Conference in March 2017. [ Read More ]

Zejula a New Maintenance Treatment Option for Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

FDA Approvals, News & Updates

On March 27, 2017, the FDA accelerated the approval of niraparib (Zejula; Tesaro), a PARP inhibitor, for maintenance treatment of 3 types of cancers—recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer—in adults who had a complete or partial response to platinum-based chemotherapy. [ Read More ]

Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management

Wayne Kuznar

NCCN 2017 Conference Highlights

Orlando, FL—Enthusiasm for immunotherapy in the treatment of cancer must be balanced with a healthy respect for the power of T-cell activation. Autoimmunity is recognized as an effect of prolonged T-cell activation via PD-1/PD ligand 1 inhibition. Although immune-related adverse events are generally easily managed, they occasionally can be fatal and therefore should be managed without delay, said Stephanie Andrews, MS, ANP-BC, a hospitalist specializing in medical oncology at Moffitt Cancer Center, Tampa, FL, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference. [ Read More ]

Longest Follow-Up in Patients with NSCLC Who Responded to Immunotherapy with Nivolumab

Phoebe Starr

AACR 2017 Highlights

Washington, DC—In the longest follow-up on single-agent nivolumab (Opdivo) to date, 5-year overall survival was 16% in patients with advanced non–small-cell lung cancer (NSCLC) in the updated results of a phase 1b dose-ranging study (CA209-003). This represents a quadrupling of 5-year overall survival with standard platinum doublets, which is approximately 4% for patients with metastatic NSCLC. [ Read More ]

Excellent Responses to Atezolizumab in Small Subset of Women with Triple-Negative Breast Cancer

Phoebe Starr

AACR 2017 Highlights, Breast Cancer

Washington, DC—Preliminary data show excellent and durable responses to atezolizumab (Tecentriq) in 10% of women with triple-negative breast cancer, one of the most aggressive and difficult-to-treat cancers. Of the responders to atezolizumab, 100% were alive at 1 year compared with only 38% of nonresponders. The trick will be to identify which women will respond to immune checkpoint inhibitor therapy. Thus far, no biomarkers for response have been identified. [ Read More ]

Integrating Patient-Reported Outcomes into Clinical Practice in Oncology

Meg Barbor, MPH

Quality Care

Orlando, FL—The term “patient-reported outcome” has become ubiquitous in cancer care. Patient-reported outcomes (PROs) are still in the early stages of being integrated into quality assessment programs and routine clinical practice, but engaging patients through PROs can be an invaluable tool for assessing and improving the quality of symptom management, said Ethan M. Basch, MD, MSc, FASCO, Director, Cancer Outcomes Research Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, at the 2017 ASCO Quality Care Symposium. [ Read More ]

Input from Patients, Families, and Caregivers Can Enhance the Quality of Patient Care

Meg Barbor, MPH

Quality Care

Orlando, FL—Establishing a Patient and Family Advisory Council for Quality (PFACQ) is one of the most direct routes to true patient-centered care, said Kate Niehaus, MBA, Chair, PFACQ, Memorial Sloan Kettering Cancer Center (MSKCC), New York City, at the 2017 ASCO Quality Care Symposium. Ms Niehaus discussed how PFACQs can be used as a mechanism for the patient’s voice. [ Read More ]

What Do We Still Need to Know About Adolescent and Young Adult Survivorship?

Chase Doyle


As a result of the differences in biology, access to care, and psychosocial and socioeconomic circumstances, adolescent and young adult (AYA) patients with cancer face distinct challenges compared with their adult counterparts. At the 2017 Cancer Survivorship Symposium, Emily S. Tonorezos, MD, MPH, General Internist, Adult Long-Term Follow-Up Program, Memorial Sloan Kettering Cancer Center, New York, NY, discussed gaps in research and treatment in this vulnerable patient population, while proposing solutions to improve AYA survivorship care. [ Read More ]

Select Clinical Trials Currently Enrolling Patients with Brain Cancer

Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with brain cancer for inclusion in investigations of new therapies or new regimens of existing treatments for patients with brain cancer. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to an appropriate clinical trial. [ Read More ]